William Ackman Nears $40 Bln Universal Music Deal : Report

Hedge-fund billionaire William Ackman's special-purpose acquisition company is nearing a deal with Vivendi-owned Universal Music Group that would value the music business at about $40 billion, the Wall Street Journal reported citing people familiar with the matter. The Prospective deal puts a valuation on the music business at $42 billion with debt.

Last month, Vivendi said it would propose the setting up of a governance structure for Universal Music Group NV, which is expected to list its shares on the Euronext Amsterdam stock exchange on September 27, 2021.

Prior to the distribution of 60% of the Universal Music Group shares to Vivendi shareholders, the group was analyzing the opportunity of selling 10% of UMG shares to an American investor or initiating a public offering of at least 5% and up to 10% of UMG shares.

Furthermore, Vivendi would retain 10% of the UMG share capital for a minimum period of two years in order to remain associated with the development of its subsidiary.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT